resTORbio, Inc. (TORC)

resTORbio, Inc. (TORC) Company Bio

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases and conditions in the United States. It is developing TORC1 inhibitor class of pharmaceutical products, including RTB101 and RTB101 with everolimus that are in Phase IIb clinical trial for the treatment of respiratory tract infections; and that have completed Phase I clinical trials for the treatment of heart failure with preserved ejection fraction and autophagy-related neurodegenerative diseases, as well as other infections, such as urinary tract infections. The company was founded in 2016 and is based in Boston, Massachusetts. resTORbio, Inc. is a subsidiary of PureTech Health plc.

TORC Daily Price Range
TORC 52-Week Price Range
Add TORC to Watchlist
Sign Up

TORC - Live POWR Rating™

Overall POWR Rating

To view TORC's real-time POWR Rating, sign up now.

Access Ratings for Free

TORC News Stream

Event/Time News Detail Start End Change
Loading, please wait...
View All TORC News

TORC Stock Chart More Charts

TORC Price/Volume Stats

Current price $6.47
Prev. close $6.44
Day low $6.39
Day high $6.85
50-day MA $8.17
200-day MA $10.59
52-week high $20.59
52-week low $6.21
Volume 305,300
Avg. volume 107,373
Dividend yield N/A
Market Cap 181.52M

TORC Social Stream

Loading social stream, please wait...

View Full TORC Social Stream

TORC Returns

1-mo -19.73%
3-mo -19.53%
6-mo -59.05%
1-year -45.08%
3-year N/A
5-year N/A
YTD -24.94%
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A
Page generated in 0.3673 seconds.